Grant Number:	3R01CA242742-03S1 Interpret this number
Primary Investigator:	Gonzalez, Brian
Organization:	H. Lee Moffitt Cancer Ctr & Res Inst
Project Title:	Identifying Disparities in Mild Cognitive Impairment and Alzheimer's Disease and Related Dementias in Diverse Prostate Cancer Survivors
Fiscal Year:	2023

PROJECT SUMMARY/ABSTRACT Mild cognitive impairment is common among people with cancer and is often a precursor to Alzheimer’s and related dementias. Recent research has focused on risk of mild cognitive impairment in prostate cancer survivors, including among patients receiving androgen deprivation therapy. For example, a recent meta-analysis found androgen deprivation therapy recipients had higher odds of dementia than controls. However, previous studies have not examined social determinants of health disparities as risk factors for mild cognitive impairment or dementia in prostate cancer. This is a significant public health issue because prostate cancer is the most common malignancy in US men and most prostate cancer patients are prescribed androgen deprivation therapy. To address this gap, this study will leverage the parent award study recruiting a diverse cohort of 250 African American, 250 Hispanic, and 250 non-Hispanic White prostate cancer survivors. This cohort overcomes limitations in the rigor of prior research that had relatively small samples of racial/ethnic minority prostate cancer survivors. All participants in the cohort will be asked to complete a validated survey of cognitive function. We conservatively estimate 200 participants in each group will join the supplement study. This will enable us to identify social determinants of health risk factors for mild cognitive impairment in prostate cancer survivorship. These risk factors will include race/ethnicity, neighborhood disadvantage measured using the Area Deprivation Index, household income, education level, and employment status. This supplement will also enable us to examine social determinants of health disparities in risk of mild cognitive impairment after receiving androgen deprivation therapy for prostate cancer. Because mild cognitive impairment is often a precursor to Alzheimer’s disease and related dementias, we will also aim to replicate these findings in a large dataset with over 1,000,000 racially and ethnically diverse prostate cancer survivors. This will enable us to identify disparities in risk of diagnosis of Alzheimer’s disease or related dementia in prostate cancer survivors, including after receiving androgen deprivation therapy. The parent award study does not currently examine any cognitive outcomes. Instead, the parent award study examines disparities and risk factors for symptom burden among PC survivors. This study complements the parent award by examining disparities in mild cognitive impairment and Alzheimer’s disease and related dementias. This study’s specific aims are to identify, among prostate cancer survivors, social determinants of health disparities in risk of 1) mild cognitive impairment, 2) mild cognitive impairment after receiving androgen deprivation therapy, and 3) Alzheimer’s disease or related dementia. This study will contribute to reducing risk of mild cognitive impairment and Alzheimer’s disease and related dementias and will improve informed decision- making and education on risks/benefits of androgen deprivation therapy for prostate cancer survivors.





None. See parent grant details.